Core Viewpoint - Brother Technology (002562) has received approval from the National Medical Products Administration for the iodine contrast agent injection, Iohexol, allowing for its official market launch in China, which enhances the company's competitiveness in the contrast agent sector [1] Group 1 - Brother Technology's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Iohexol injection [1] - Iohexol injection is primarily used for various types of angiography and CT enhancement examinations, characterized by low viscosity and good safety [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product and expanding its iodine contrast agent product line [1]